Literature DB >> 29109763

Survivin and XIAP expression in distinct tumor compartments of surgically resected gastric cancer: XIAP as a prognostic marker in diffuse and mixed type adenocarcinomas.

Levent Dizdar1, Monika Tomczak1, Thomas A Werner1, Sami A Safi1, Jasmin C Riemer2, Pablo E Verde3, Nikolas H Stoecklein1, Wolfram T Knoefel1, Andreas Krieg1.   

Abstract

There is considerable evidence that the inhibitor of apoptosis protein (IAP) family serves a role in tumorigenesis. The most studied IAP family members, survivin and X-linked inhibitor of apoptosis (XIAP), have been demonstrated to serve as biomarkers in distinct tumor entities. Thus, the present study aimed to investigate the expression levels of both IAPs in the tumor center, invasion front and lymph node metastases of surgically resected gastric cancer (GC) specimens. Tissue microarrays containing samples from 201 primary GCs were analyzed. IAP expression was detected using immunohistochemistry in different tumor compartments, normal mucosa and lymph node metastases. In addition, the association between the expression levels of these proteins, and clinicopathological parameters and overall survival was investigated. High levels of survivin and XIAP were evident in GC, when compared with normal mucosa, and were correlated with intestinal-type and well-differentiated GC, as well as low International Union Against Cancer stages. Increased XIAP expression was detected in lymph node metastases as compared with corresponding primary tumors. XIAP overexpression was identified to be an independent negative prognostic marker in diffuse and mixed type GC. These results suggest a potential role of survivin and XIAP in the early phase of gastric carcinogenesis. In addition, increased XIAP expression in lymph node metastases supports the observation that IAPs serve an essential role in metastatic tumor disease. Since XIAP expression was identified to be associated with poor survival in diffuse and mixed type GC, XIAP may serve as a novel therapeutic target in these types of GC.

Entities:  

Keywords:  XIAP; gastric cancer; prognostic marker; survivin

Year:  2017        PMID: 29109763      PMCID: PMC5661605          DOI: 10.3892/ol.2017.6999

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  51 in total

1.  Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection.

Authors:  Takehiko Dohi; Fang Xia; Dario C Altieri
Journal:  Mol Cell       Date:  2007-07-06       Impact factor: 17.970

2.  IAPs and their emergent role in NLR signaling.

Authors:  Andreas Krieg; John C Reed
Journal:  Cell Cycle       Date:  2010-02-20       Impact factor: 4.534

3.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.

Authors:  Alicia F C Okines; Sue E Ashley; David Cunningham; Jacqueline Oates; Andrea Turner; Janine Webb; Claire Saffery; Yu Jo Chua; Ian Chau
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

4.  TFF3 and survivin expressions associate with a lower survival rate in gastric cancer.

Authors:  Jia-Rong Meng; Hui-Zhong Tang; Kai-Zong Zhou; Wu-Hong Shen; He-Yi Guo
Journal:  Clin Exp Med       Date:  2012-09-21       Impact factor: 3.984

5.  Prognostic significance and different properties of survivin splicing variants in gastric cancer.

Authors:  Hua Meng; Caide Lu; Hideaki Mabuchi; Nobuhiko Tanigawa
Journal:  Cancer Lett       Date:  2004-12-28       Impact factor: 8.679

6.  Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).

Authors:  Francesco Giuliani; Stefano Molica; Evaristo Maiello; C Battaglia; Vittorio Gebbia; Maurizio Di Bisceglie; Gianluca Vinciarelli; Nicola Gebbia; Giuseppe Colucci
Journal:  Am J Clin Oncol       Date:  2005-12       Impact factor: 2.339

7.  An anti-apoptosis gene, survivin and telomerase expression in gastric cancer.

Authors:  Akira Tsuburaya; Yoshikazu Noguchi; Takaki Yoshikawa; Aya Saito; Chiharu Doi; Takahide Okamoto; Kuniyasu Fukuzawa
Journal:  Hepatogastroenterology       Date:  2002 Jul-Aug

8.  Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.

Authors:  Arnaud D Roth; Nicola Fazio; Roger Stupp; Stephen Falk; Jürg Bernhard; Piercarlo Saletti; Dieter Köberle; Markus M Borner; Kaspar Rufibach; Rudolf Maibach; Martin Wernli; Martin Leslie; Robert Glynne-Jones; Lukas Widmer; Matthew Seymour; Filippo de Braud
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

Review 9.  New wirings in the survivin networks.

Authors:  D C Altieri
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

10.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

Authors:  Takahito Nakahara; Aya Kita; Kentaro Yamanaka; Masamichi Mori; Nobuaki Amino; Masahiro Takeuchi; Fumiko Tominaga; Shinji Hatakeyama; Isao Kinoyama; Akira Matsuhisa; Masafumi Kudoh; Masao Sasamata
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 13.312

View more
  4 in total

1.  Dysregulated Expression of Apoptosis-Associated Genes and MicroRNAs and Their Involvement in Gastric Carcinogenesis.

Authors:  Mayara Luciana Sallas; Diana Zapparoli; Mônica Pezenatto Dos Santos; Jéssica Nunes Pereira; Wilson Aparecido Orcini; Rita Luiza Peruquetti; Elizabeth Suchi Chen; Marilia de Arruda Cardoso Smith; Spencer Luiz Marques Payão; Lucas Trevizani Rasmussen
Journal:  J Gastrointest Cancer       Date:  2021-06

Review 2.  The Biological Activities and Therapeutic Potentials of Baicalein Extracted from Oroxylum indicum: A Systematic Review.

Authors:  Nik Nur Hakimah Nik Salleh; Farah Amna Othman; Nur Alisa Kamarudin; Suat Cheng Tan
Journal:  Molecules       Date:  2020-12-02       Impact factor: 4.411

3.  Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment.

Authors:  Christian Vay; Philipp M Schlünder; Levent Dizdar; Irene Esposito; Markus P H Ghadimi; Wolfram T Knoefel; Andreas Krieg
Journal:  J Cancer Res Clin Oncol       Date:  2021-12-03       Impact factor: 4.322

4.  Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Christian Vay; Shahrooz Babaei; Sami-Alexander Safi; Levent Dizdar; Alexander Rehders; Lena Haeberle; Christoph Roderburg; Sven H Loosen; Irene Esposito; Wolfram T Knoefel; Andreas Krieg
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.